HistoRx (www.historx.com) is proviging Radiation Therapy Oncology Group (RTOG; www.rtog.org) researchers with access to its Aqua® technology for biomarker analysis. HistoRx intends to commercialize assays and reagents developed in the course of the alliance for clinical use as predictive diagnostics. RTOG, an NCI-funded clinical cooperative group, will investigate the relationship between specific protein biomarkers and clinical responsiveness in brain tumor patients using customized immunohistochemical assays.

This site uses Akismet to reduce spam. Learn how your comment data is processed.